HTP antimalarial screen

In the search for new drugs that target the malarial parasite Plasmodium sp., researchers need methods for screening small molecule libraries that offer higher throughputs than the current Giesma staining or radiolabeling methods.
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
BOSTON—In the search for new drugs that target the malarial parasite Plasmodium sp., researchers need methods for screening small molecule libraries that offer higher throughputs than the current Giesma staining or radiolabeling methods. Answering this challenge, scientists at Harvard Medical School and Harvard School of Public Health developed a fluorescent DNA staining technique that is amenable to automation and high-throughput screening.
As they described in Antimicrobial Agents and Chemotherapy, the researchers first determined that the fluorescent dye DAPI exhibited higher S/N when used to stain parasite DNA in infected erythrocytes than either PicoGreen or SYBR Green 1.
Furthermore, when they compared the ability of dye staining to detect infection to the standard 3H-hypoxanthine incorporation assay, the researchers found the DAPI staining was equally sensitive when using a standard plate reader. The dye method was even more sensitive, however, when screened with an automated microscope—in this case, the CellWorX imaging platform.
The researchers then determined the IC50 values of common antimalarials using DAPI staining or radiolabling and found the two methods offered comparable results. Furthermore, the DAPI assay was easily optimized to work not only in 96-well plates, but also 384-well plates. And when they used the assay to screen a library of almost 80,000 small molecules, the researchers identified 900 compounds with antimalarial activity, which they expect to further characterize.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up of a researcher using a stylus to draw or interact with digital molecular structures on a blue scientific interface.
When molecules outgrow the limits of sketches and strings, researchers need a new way to describe and communicate them.
Portrait of Scott Weitze, Vice President of Research and Technical Standards at My Green Lab, beside text that reads “Tell us what you know: Bringing sustainability into scientific research,” with the My Green Lab logo.
Laboratories account for a surprising share of global emissions and plastic waste, making sustainability a priority for modern research.
3D illustration of RNA molecules on a gradient blue background.
With diverse emerging modalities and innovative delivery strategies, RNA therapeutics are tackling complex diseases and unmet medical needs.
Drug Discovery News September 2025 Issue
Latest IssueVolume 21 • Issue 3 • September 2025

September 2025

September 2025 Issue

Explore this issue